Skip to content

Content transparency

  • Published:
  • Updated:
  • Editorial record: · no verified named reviewer is attached
  • Sources: 4 references listed
Authorship, review and conflicts
Named author
No verified public author identity is recorded for this page. Dog Tumor is the publisher; no veterinary authorship is implied.
Clinical review
No verified named veterinary or subject-matter reviewer is recorded for this page.
Conflicts
No page-specific conflict statement is recorded. Read the editorial standards.
Directory Entry

Furosemide as a Cyclophosphamide Uroprotection Adjunct in Dogs

Prescription Drug · Supportive-care medicine · Cyclophosphamide bladder-protection strategies · Dogs · During Chemotherapy · Published Study · Veterinary Clinical Use
Common name: furosemide used as a protocol adjunctEditorial source check: Dog Tumor Editorial Team (editorial review; not licensed veterinary review)Last reviewed: Aug 12, 2026Official link: Visit
Directory entry:This page explains what the product, drug, herb, chemotherapy approach, or supportive-care option is. For step-by-step use or monitoring, read related Guides and consult a veterinarian.
Entry kind
Supportive care
Product family
Cyclophosphamide bladder-protection strategies

Quick summary

furosemide used as a protocol adjunct is covered as loop diuretic used within selected canine cyclophosphamide protocols; not antitumour therapy, with species, evidence, regulatory, safety, interaction and monitoring boundaries for a veterinarian-led decision.

What it is

Loop diuretic used within selected canine cyclophosphamide protocols; not antitumour therapy. Furosemide.

Active ingredients / formula

Furosemide.

Mechanism / rationale

Furosemide increases urine production, which can dilute and shorten bladder contact with acrolein, a urotoxic cyclophosphamide metabolite. It does not neutralise acrolein or protect marrow.

How it is discussed in tumor care

AAHA recommends administration with cyclophosphamide in dogs to decrease sterile haemorrhagic cystitis. This is a protocol relationship, not a reason to give a diuretic independently at home.

Potential role

AAHA recommends administration with cyclophosphamide in dogs to decrease sterile haemorrhagic cystitis. This is a protocol relationship, not a reason to give a diuretic independently at home.

Typical use context

Veterinarian-directed adjunct tied to the chemotherapy plan

Evidence snapshot

Retrospective canine studies found lower cystitis incidence with concurrent furosemide or mesna than without prophylaxis. Retrospective association does not establish zero risk, and metronomic and maximally tolerated protocols are not identical.

Safety notes

Diuresis can worsen dehydration, electrolyte imbalance, low blood pressure or kidney stress. Urinary obstruction or reduced access to water and elimination changes the risk substantially.

Interactions / cautions

Other diuretics, kidney-active medicines, NSAIDs and dehydration require review. Timing relative to cyclophosphamide and planned access to water and urination is part of the clinic protocol.

Regulatory status

This page describes extra-label protocol use; it is not an FDA-approved canine cancer indication for furosemide.

Regions, labels and market differences

Multi-region veterinary protocol use; local rules and practice vary.

Monitoring plan

The team assesses hydration, kidney values, electrolytes, urinary history and household ability to provide safe elimination. Owners monitor thirst, urination, weakness, vomiting and any blood or pain with urination. Suspected cystitis requires veterinary evaluation and may permanently change the chemotherapy plan.

Questions to ask your veterinarian

  • Does the confirmed diagnosis and species match the evidence population?
  • What is labelled, conditionally authorised or extra-label in this region?
  • Which objective findings will define benefit, toxicity and a change in plan?
  • What household handling, waste and urgent-contact instructions apply?

Sources and further reading